Do not hesitate to contact us if you want to meet our team during this meeting.
Do not miss the presentation on November 20, 2019 at 16:45 "Development of a next generation immune checkpoint modulator towards the clinic; a humanized BTN3A antibody (ICT01) activating gamm9delta2 T cells"
by Prof. René Hoet, PhD, CSO, ImCheck Therapeutics
ImCheck Therapeutics is advancing the first activating butyrophilin BTN3A (CD277) antibody towards the clinic. The humanized antibody to BTN3A, ICT01, specifically activates human gamma9delta2 T cells in vitro and in vivo and is planned to enter Phase I studies in early 2020. Additionally, therapeutic antibodies against 5 novel butyrophilins are currently validated. This opens a completely new space that is clearly different from the current B7/CD28 superfamily targets and has the potential to become the next generation immune checkpoint modulators.